Covered recipient · General Payments record
GEORGE ANSSTAS
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$119,482.06
121 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,305.00 | 24 |
| Consulting Fee | $33,577.50 | 8 |
| Travel and Lodging | $14,277.88 | 38 |
| Honoraria | $5,400.00 | 2 |
| Food and Beverage | $2,921.68 | 49 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34,416.19 | 20 |
| Regeneron Healthcare Solutions, Inc. | $21,481.82 | 15 |
| Merck Sharp & Dohme Corporation | $14,109.84 | 20 |
| GENZYME CORPORATION | $11,589.36 | 15 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $11,001.59 | 12 |
| EMD Serono, Inc. | $8,183.92 | 11 |
| Novocure Inc. | $7,912.46 | 19 |
| AstraZeneca Pharmaceuticals LP | $5,600.00 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $5,061.88 | 6 |
| Novo Nordisk Inc | $125.00 | 1 |
Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GEORGE ANSSTAS
NPI 1790988053 · CMS profile ID 927175
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
SAINT LOUIS, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- GEORGE ANSSTAS, NPI 1790988053, CMS profile ID 927175, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790988053?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
121 matching records · $119,482.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–121 of 121.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novocure Inc. | $1,092.00 | 03/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573963 | CMS |
| Novocure Inc. | $101.64 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573959 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,125.00 | 03/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323241 | CMS |
| Novocure Inc. | $94.12 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573975 | CMS |
| Novocure Inc. | $79.45 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573977 | CMS |
| Novocure Inc. | $152.00 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573979 | CMS |
| Novo Nordisk Inc | $125.00 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703505777 | CMS |
| E.R. Squibb & Sons, L.L.C. | $796.50 | 02/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323243 | CMS |
| E.R. Squibb & Sons, L.L.C. | $88.81 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323245 | CMS |
| Novocure Inc. | $271.27 | 02/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573981 | CMS |
| GENZYME CORPORATION | $25.00 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693981811 | CMS |
| Novocure Inc. | $2.00 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573953 | CMS |
| Novocure Inc. | $21.68 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573957 | CMS |
| E.R. Squibb & Sons, L.L.C. | $4,125.00 | 02/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323237 | CMS |
| E.R. Squibb & Sons, L.L.C. | $742.34 | 01/31/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323227 | CMS |
| E.R. Squibb & Sons, L.L.C. | $56.44 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323233 | CMS |
| Novocure Inc. | $5.00 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573965 | CMS |
| Novocure Inc. | $432.41 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 677573973 | CMS |
| GENZYME CORPORATION | $25.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693981307 | CMS |
| E.R. Squibb & Sons, L.L.C. | $42.41 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323231 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.00 | 01/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651323239 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $697,533.50 | 85 |
| PY2024 | Recipient | $1,174.71 | 3 |
| PY2024 | Principal investigator | $597,399.65 | 57 |
| PY2023 | Recipient | $806.21 | 10 |
| PY2023 | Principal investigator | $655,293.21 | 71 |
| PY2022 | Recipient | $817.92 | 8 |
| PY2022 | Principal investigator | $988,845.99 | 77 |
| PY2021 | Recipient | $1,270.00 | 2 |
| PY2021 | Principal investigator | $498,672.90 | 40 |
| PY2020 | Principal investigator | $524,263.95 | 35 |
| PY2019 | Principal investigator | $261,314.14 | 17 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
85 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,000.00 | 12/31/2025 | Non-covered Recipient Entity Washington University | IOV-EAP-402 | No dispute reported | 06/30/2026 | 1252498403 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,894.34 | 12/31/2025 | Non-covered Recipient Entity Washington University School of Medicine | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group | No dispute reported | 06/30/2026 | 1232925145 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,443.75 | 12/31/2025 | Non-covered Recipient Entity Siteman Cancer Center | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 | No dispute reported | 06/30/2026 | 1232926871 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $31,824.00 | 12/22/2025 | Non-covered Recipient Entity Washington University School of Medicine in St. Louis | A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1232935877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,889.90 | 12/19/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184278862 |
| Principal investigator 1 | Immunocore Limited | $4,825.86 | 12/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144137 |
| Principal investigator 1 | Immunocore Limited | $6,468.06 | 12/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144139 |
| Principal investigator 1 | Immunocore Limited | $3,007.02 | 12/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144141 |
| Principal investigator 1 | Genentech, Inc. | $24,707.40 | 12/12/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684430 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,980.00 | 12/04/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184269001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $375.30 | 11/26/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184265559 |
| Principal investigator 1 | Immunocore Limited | $4,700.28 | 11/19/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144131 |
| Principal investigator 1 | Immunocore Limited | $621.00 | 11/19/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144133 |
| Principal investigator 1 | Immunocore Limited | $7,079.40 | 11/19/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144135 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,291.50 | 11/14/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184261205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,545.05 | 11/14/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184261207 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $153.90 | 11/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184257733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,445.80 | 11/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184257735 |
| Principal investigator 1 | Genentech, Inc. | $1,069.00 | 10/31/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684418 |
| Principal investigator 1 | Genentech, Inc. | $1,645.20 | 10/31/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,705.20 | 10/23/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184252530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,997.81 | 10/16/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184250551 |
| Principal investigator 1 | Immunocore Limited | $8,000.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144143 |
| Principal investigator 1 | Immunocore Limited | $8,400.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144145 |
| Principal investigator 1 | Immunocore Limited | $4,600.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144147 |
| Principal investigator 1 | Immunocore Limited | $1,015.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144149 |
| Principal investigator 1 | Immunocore Limited | $6,900.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144151 |
| Principal investigator 1 | Immunocore Limited | $1,015.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144153 |
| Principal investigator 1 | Immunocore Limited | $2,900.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144155 |
| Principal investigator 1 | Immunocore Limited | $2,300.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144157 |
| Principal investigator 1 | Immunocore Limited | $690.00 | 10/15/2025 | Non-covered Recipient Entity Washington University | Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | No dispute reported | 06/30/2026 | 1212144159 |
| Principal investigator 1 | Genentech, Inc. | $9,928.00 | 10/10/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,404.90 | 10/03/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184244593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,533.70 | 09/18/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184240414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,980.00 | 09/11/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184236071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,545.05 | 09/04/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184235139 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,997.81 | 08/26/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184230637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,291.50 | 08/21/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184229921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,641.54 | 08/21/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184229923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,536.20 | 08/21/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184229925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,230.20 | 08/07/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184226529 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,054.70 | 08/01/2025 | Non-covered Recipient Entity Washington University | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence | No dispute reported | 06/30/2026 | 1235991865 |
| Principal investigator 1 | ModernaTX, Inc. | $16,944.57 | 08/01/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252985036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,639.35 | 07/31/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184222784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,829.28 | 07/31/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184222786 |
| Principal investigator 1 | ModernaTX, Inc. | $232.20 | 07/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252985030 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,997.81 | 07/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184217681 |
| Principal investigator 1 | Genentech, Inc. | $3,175.31 | 07/16/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684414 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,134.81 | 07/03/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184212635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,114.00 | 06/24/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184210608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,216.60 | 06/19/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184209093 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,937.44 | 06/12/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184206171 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $90,191.88 | 06/05/2025 | Non-covered Recipient Entity Washington University | A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235991867 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,404.90 | 06/05/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184204115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,061.00 | 05/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184197521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,964.09 | 05/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184197523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,003.50 | 05/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184197525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,667.82 | 05/15/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184194585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,281.40 | 05/15/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184194587 |
| Principal investigator 1 | Genentech, Inc. | $3,583.80 | 05/09/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684410 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,130.43 | 05/02/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184191911 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,352.60 | 05/02/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184191913 |
| Principal investigator 1 | ModernaTX, Inc. | $18,460.71 | 04/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252985034 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,997.81 | 04/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184185257 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,520.00 | 04/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184185259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,650.00 | 04/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184185261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,888.00 | 04/22/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184185263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,971.16 | 04/17/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184184762 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,325.12 | 04/16/2025 | Non-covered Recipient Entity Washington University School of Medicine | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group | No dispute reported | 06/30/2026 | 1232925189 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $16,380.00 | 04/04/2025 | Non-covered Recipient Entity Washington University School Of Medicine | A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235991813 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $85,377.88 | 04/03/2025 | Non-covered Recipient Entity Washington University | A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1235991863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,911.50 | 04/03/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184181626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,880.80 | 03/20/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma | No dispute reported | 06/30/2026 | 1184175010 |
| Principal investigator 1 | Genentech, Inc. | $1,000.00 | 03/11/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | No dispute reported | 06/30/2026 | 1211684456 |
| Principal investigator 1 | Genentech, Inc. | $1,645.20 | 03/07/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | Ph 2 Randomized POC Study of PCV in 1L Melanoma | No dispute reported | 06/30/2026 | 1211684408 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,900.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157137 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,650.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157139 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157141 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,705.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157143 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,300.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157145 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,600.00 | 03/06/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | No dispute reported | 06/30/2026 | 1184157147 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $34,407.05 | 02/06/2025 | Non-covered Recipient Entity Washington University School Of Medicine | A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1235991815 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,696.40 | 01/29/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184149830 |
| Principal investigator 1 | ModernaTX, Inc. | $31,865.81 | 01/16/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | No dispute reported | 06/30/2026 | 1252985032 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,404.90 | 01/03/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1184144800 |